Highlights from ASCO
June 5, 2023
Dr Claudio Cerchione summarised the educational session on the management of multiple myeloma in special patient populations, such as elderly and patients with renal failure.
From 2 June till 6 June 2023: HIGHLIGHTS FROM ASCO
Your direct line with Chicago
The American Society of Clinical Oncology (ASCO) 2023 brings together leading experts in the different fields of cancer from around the world. And, as usual, they gather together in Chicago, USA. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
With the support of:
Daily highlights
Project in the spotlight
icml lugano 2025 in depth 1
May 11, 2025
The ALLELE trial is investigating tabelecleucel to treat relapsed/refractory EBV-associated PTLD disease (R/R EBV+ PTLD) arising after a solid organ transplant (SOT) or a hematopoietic stem cell transplant (HSCT). In
eha milan 2025 in depth 1
May 11, 2025
In this video, Prof Daan Dierickx, hematologist at the University Hospitals Leuven, discusses the updated results of this trial presented during EBMT 2025.
The ALLELE trial
April 11, 2025
In this video, Prof Daan Dierickx, hematologist at the University Hospitals Leuven, discusses the updated results of this trial presented during EBMT 2025.
Quality standards
April 11, 2025
In this video, Prof Dr Ivan Van Riet discusses the recent update of the JACIE quality standards for the accreditation of cell therapy centers in Europe. These quality standards are
AML transplant or not
April 11, 2025
In this video, Prof Charles Craddock discusses how improvements in the pre- and post-transplant management of these patients can lead to better outcomes.
Conception after transplant
April 10, 2025
During EBMT 20225, Ms Iebe De Quick, nurse and oncofertility coordinator at Brussels IVF, delivered a presentation on the available options for fertility presentation in oncological patients.
OS21-07 – MDS very poor risk
April 10, 2025
During EBMT 2025, Prof Dr Xavier Poiré presented the results of an analysis performed by the EBMT chronic malignancies working party looking into the outcome of MDS patients with very
Nurse symposia
April 10, 2025
During EBMT 2025, Ms. Marijke Quaghebeur chaired an interesting series of sessions dedicated to nurses working in stem cell transplantation and cell therapy.
In-depth stories
icml lugano 2025 in depth 1
May 11, 2025
The ALLELE trial is investigating tabelecleucel to treat relapsed/refractory EBV-associated PTLD disease (R/R EBV+ PTLD) arising after a solid organ transplant (SOT) or a hematopoietic stem cell transplant (HSCT). In
eha milan 2025 in depth 1
May 11, 2025
In this video, Prof Daan Dierickx, hematologist at the University Hospitals Leuven, discusses the updated results of this trial presented during EBMT 2025.
The ALLELE trial
April 11, 2025
In this video, Prof Daan Dierickx, hematologist at the University Hospitals Leuven, discusses the updated results of this trial presented during EBMT 2025.
Quality standards
April 11, 2025
In this video, Prof Dr Ivan Van Riet discusses the recent update of the JACIE quality standards for the accreditation of cell therapy centers in Europe. These quality standards are
AML transplant or not
April 11, 2025
In this video, Prof Charles Craddock discusses how improvements in the pre- and post-transplant management of these patients can lead to better outcomes.
Conception after transplant
April 10, 2025
During EBMT 20225, Ms Iebe De Quick, nurse and oncofertility coordinator at Brussels IVF, delivered a presentation on the available options for fertility presentation in oncological patients.
OS21-07 – MDS very poor risk
April 10, 2025
During EBMT 2025, Prof Dr Xavier Poiré presented the results of an analysis performed by the EBMT chronic malignancies working party looking into the outcome of MDS patients with very
Nurse symposia
April 10, 2025
During EBMT 2025, Ms. Marijke Quaghebeur chaired an interesting series of sessions dedicated to nurses working in stem cell transplantation and cell therapy.
Poster selection
Functional characterisation of kdm6b in immature leukemia
July 17, 2024
Cristina Borin, a doctoral researcher at the University of Ghent and the Cancer Research Institute Ghent (CRIG) presented her work on the functional characterization of Kdm6b in immature leukemia. Her
Transfusion practice for sickle cell disease in a Belgian reference centre
July 17, 2024
Dr Yvan Momo, a haematologist at the Hopital Universitaire de Bruxelles in Brussels, presents an analysis of transfusion practices in a Belgian sickle cell reference centre, assessing their adherence to
Brentuximab vedotin + pembrolizumab in R/R cHL
July 17, 2024
The current standard treatment for R/R cHL involves salvage chemotherapy followed by ASCT. However, the optimal salvage therapy regimen remains undefined. Recent evidence suggests that the combination of brentuximab vedotin
Dual targeting of EZH2 and HDAC in haematological malignancies
July 17, 2024
Thomas Slegers, a doctoral researcher, and Dr Marlies Vanden Bempt, a postdoctoral researcher, both from KU Leuven, presented their research on the dual targeting of EZH2 and HDAC in haematological
The PREAMBLE registry
July 10, 2024
Prof Dr Claudio Cerchione, a haematologist at the Istituto Romagnolo per lo Studio dei Tumori in Meldola, Italy, shares insights from the PREAMBLE registry. This registry documents treatment patterns and
QuANTUM-First: Efficacy by age in newly diagnosed FLT3-ITD–positive AML
July 1, 2024
Dr Pau Montesinos, a haematologist at the Hospital Universitario y Politècnico La Fe in Valencia, Spain, presented a post hoc analysis of the phase 3 QuANTUM-First study. This analysis evaluated
The Impact of Isatuximab HGG in R/R MM patients
December 13, 2023
Dr Cesar Rodriguez, affiliated with Mount Sinai in New York, presents a research study examining the impact of isatuximab (Isa) on the occurrence of hypogammaglobulinemia (HGG) and the concomitant risk
AML real world evidence initiative: venetoclax versus control in patients unfit for intensive chemotherapy
December 13, 2023
In this study, Dr Aaron Goldberg from the Memorial Sloan Kettering Cancer Center presents a comparative analysis of outcomes and healthcare research utilization in patients with AML treated with venetoclax